Human Papillomavirus Vaccination: Progress and Challenges in Global Immunization Strategies
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Vaccines and Therapeutic Developments".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 3
Special Issue Editor
Interests: papillomavirus; gynecological cancer; infectious diseases; vaccines; surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human papillomavirus (HPV) vaccination represents a cornerstone in preventing HPV-related cancers, yet global implementation faces significant challenges. While vaccine efficacy is well-established, coverage remains inequitable, particularly in low- and middle-income countries where accessibility and cost present major barriers. Recent developments, including the WHO's endorsement of single-dose schedules and next-generation vaccines, are reshaping immunization strategies. Clinical knowledge about HPV vaccination is growing year after year: we have moved from primary prevention in girls to gender-neutral vaccination, now reaching new developments such as adult women vaccination.
This Special Issue seeks original research and reviews addressing key aspects of HPV vaccination: optimizing delivery strategies, overcoming vaccine hesitancy, improving dose schedule efficiency, and advancing equitable access. Studies evaluating innovative approaches in resource-limited settings as well as basic research about HPV vaccines and immunology are particularly welcome. Contributions will support the global effort to eliminate HPV-related cancers through improved vaccination policies and practices.
Dr. Alessandro Ghelardi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human papillomavirus
- HPV
- vaccine
- immunization strategies
- vaccine equity
- single-dose schedule
- vaccine hesitancy
- global health
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
